AI-powered cardiac imaging analysis for coronary artery disease diagnosis
Cleerly builds AI models trained on CT imaging to diagnose coronary artery disease and prevent heart attacks. The company is scaling a regulated medical-device platform: engineering-heavy hiring (15 roles), active deployment of ML models for imaging analysis, and a product roadmap focused on enterprise integrations and third-party AI engine connections. Core challenges are regulatory approval velocity and reliability of diagnostic algorithms in production.
Notable leadership hires: Backend Lead, Regional Sales Director
Cleerly develops AI-empowered diagnostic software for coronary artery disease, grounded in clinical trial data spanning nearly two decades. The platform automates analysis of non-invasive CT imaging to support cardiologists and health systems in risk stratification and treatment planning. Founded in 2017 and based in Denver, Cleerly operates across the U.S. and Portugal with 201–500 employees. The company sells to hospitals and health systems; revenue models likely include software licensing and per-scan or per-patient fees typical of medical-device SaaS. Current product work centers on next-generation imaging platforms, quantitative diagnosis tools, and scalable AI pipelines required for enterprise hospital deployment.
Cleerly runs on AWS, Python, Salesforce, and Looker for analytics. Engineering uses Jira and Confluence; teams collaborate via Slack, Zoom, and Google Workspace. Recently adopting JAMF and Kandji for device management.
Cleerly is headquartered in Denver, Colorado. The company also hires in Portugal and maintains active operations in the United States.
Other companies in the same industry, closest in size